Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay's lead program includes FPI-1434, which is in clinical trial. Fusion Pharmaceuticals Inc. is based in Hamilton, Canada.
| Revenue (Most Recent Fiscal Year) | $2.07M |
| Net Income (Most Recent Fiscal Year) | $-94.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 816.36 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.91 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4550.77% |
| Net Margin (Trailing 12 Months) | -4136.55% |
| Return on Equity (Trailing 12 Months) | -46.59% |
| Return on Assets (Trailing 12 Months) | -35.34% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.16 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.39 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 84.86M |
| Free Float | 78.29M |
| Market Capitalization | $1.80B |
| Average Volume (Last 20 Days) | 1.65M |
| Beta (Past 60 Months) | -0.72 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.75% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.85% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |